High levels of VRK1 confer resistance to different treatments based on DNA damage; thus, VRK1 overexpression has been associated with poorer prognosis in some types of cancer, including multiple myeloma and lung cancer [4]. Here, VRK1 is linked to plasma cell myeloma.